mdco-216
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02678923)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Apolipoprotein A-IINHIBITOR
APOA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mdco-216
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02678923 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | South Australian Health and Medical Research Institute, The Medicines Company, University of Rochester |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| South Australian Health and Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| The Medicines Company | For profit | 1 | 1 | 1 | 2015 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1